# Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT

> **NCT01810120** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mariella Enoc** · enrollment: 30 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Leukemia Acute Myeloid - AML
- Non-Hodgkin Lymphoma
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** TCR alfa beta T cell depletion

## Key facts

- **NCT ID:** NCT01810120
- **Lead sponsor:** Mariella Enoc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01810120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01810120, "Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01810120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*